Drug details

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide tablets)

type of HIV, ART Combos

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a three-drug combination of a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and two HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

The drug is often used to treat HIV .

This drug may have the following side effects:
  • nausea,
  • loss of appetite,
  • itching,
  • dark urine,
  • rash,
  • vomiting,
  • diarrhea,
  • fever,
  • chills,
  • severe drowsiness,
  • stomach pain,
  • dizziness,
  • joint pain,
  • coughing,
  • nervousness,
  • fast or shallow breathing,
  • unusual tiredness,
  • fast, pounding or irregular heartbeat,
  • irritability,
  • trouble breathing,
  • vision changes,
  • severe tiredness,
  • severe dizziness
  • trouble speaking,
  • change in the amount of urine,
  • swollen lymph nodes,
  • pink or bloody urine,
  • yellowing of the eyes and skin (jaundice),
  • blue or cold skin,
  • muscle pain,
  • slow or irregular heartbeat,
  • unexplained weight loss,
  • muscle aches or weakness,
  • severe headaches,
  • numbness or tingling of the hands, feet, arms, or legs,
  • non-healing skin sores,
  • heat intolerance,
  • bulging eyes,
  • unusual growth in the neck (goiter),
  • difficulty swallowing,
  • difficulty moving your eyes,
  • dropping face,
  • paralysis,
  • swelling of the face, tongue, or throat, and
The following drugs are related to Biktarvy, either as a replacement or used together:
  • Kivexa (abacavir and lamivudine film-coated tablets)
  • Cabenuva (cabotegravir; rilpivirine extended-release injectable suspension)
  • Vocabria (cabotegravir tablets for oral use)
  • Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir  alafenamide tablets)
  • Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate tablets)
  • Dovato (dolutegravir and lamivudine tablets)
  • Pifeltro (doravirine tablets)
  • Rukobia (fostemsavir extended-release tablets)